One year after Fran Sverdrup came to Saint Louis University to do medical research, his daughter was found to have a rare disease that had no treatment. Go find one, his boss urged.
The licensing of these compounds is an important step towards Antegrin’s commercialization of effective integrin-targeting therapies.
Contract Will Accelerate Muscular Dystrophy Research
SLU Researchers Find Molecule that Previously Prevented Scarring Works in Another Organ
With proof-of-principle in his pocket and a new $2.2 million grant from the National Institutes of Health (NIH), SLU scientist John Tavis, Ph.D., will take his 25 year mission to finally develop a cure for the hepatitis B virus into the next phase.
UCSF-Led Study Uses Drug to Target Fibrosis of Lungs, Liver and Kidney